Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Capital Leases (2016 - 2022)

Historic Capital Leases for Ernexa Therapeutics (ERNA) over the last 12 years, with Q3 2022 value amounting to $6000.0.

  • Ernexa Therapeutics' Capital Leases changed N/A to $6000.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $6000.0, marking a year-over-year change of. This contributed to the annual value of $20000.0 for FY2019, which is 5121.95% down from last year.
  • Latest data reveals that Ernexa Therapeutics reported Capital Leases of $6000.0 as of Q3 2022.
  • Ernexa Therapeutics' Capital Leases' 5-year high stood at $114000.0 during Q1 2018, with a 5-year trough of $4000.0 in Q3 2020.
  • For the 4-year period, Ernexa Therapeutics' Capital Leases averaged around $38272.7, with its median value being $31000.0 (2019).
  • Its Capital Leases has fluctuated over the past 5 years, first tumbled by 4791.67% in 2019, then plummeted by 8400.0% in 2020.
  • Quarter analysis of 4 years shows Ernexa Therapeutics' Capital Leases stood at $41000.0 in 2018, then plummeted by 51.22% to $20000.0 in 2019, then crashed by 80.0% to $4000.0 in 2020, then skyrocketed by 50.0% to $6000.0 in 2022.
  • Its last three reported values are $6000.0 in Q3 2022, $4000.0 for Q3 2020, and $15000.0 during Q1 2020.